Product Information
GABAPENTIN 800 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.0883 per EA under NDC 50228017801. Its NADAC has been published 394 times since Mar 20, 2019.
FDA first approved this application on Feb 4, 2016. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
800 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228017801
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA205101FDA Approved
2/4/2016
TE Code
AB1
On Market Since
2/4/2016
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 800 MG TABLET has been published 394 times since Mar 20, 2019, and over the history we have for it it has declined 28.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0883 per EA |
|---|---|
| All-time high | $0.1374 (Jan 15, 2020) |
| All-time low | $0.0799 (Nov 20, 2024) |
| 52-week high | $0.1016 |
| 52-week low | $0.0883 |
| Median price | $0.1236 |
| Average price | $0.1177 |
| Largest weekly change | -27.0% (Nov 20, 2024) |
| Weeks tracked | 394 |
| Tracking since | Mar 20, 2019 |
Generic Alternatives
The matcher finds 21 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN 800 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 800 MG TABLET, manufactured by ScieGen Pharmaceuticals, Inc., is $0.0883 per EA (NDC 50228017801), effective Sep 30, 2026.
How has the price of GABAPENTIN 800 MG TABLET changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 800 MG TABLET has declined 28.2%. It has been tracked across 394 weekly CMS publications since Mar 20, 2019.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 800 MG TABLET?
Since Mar 20, 2019, the NADAC for GABAPENTIN 800 MG TABLET has ranged from a low of $0.0799 (Nov 20, 2024) to a high of $0.1374 (Jan 15, 2020), with a median of $0.1236 per EA.
Are there cheaper alternatives to GABAPENTIN 800 MG TABLET?
21 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GABAPENTIN 800 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GABAPENTIN 800 MG TABLET?
GABAPENTIN 800 MG TABLET (NDC 50228017801) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.